Chemed (CHE) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary
Event summary combining transcript, slides, and related documents.
43rd Annual J.P. Morgan Healthcare Conference 2025 summary
10 Jan, 2026Company history and business structure
Originated from a 1971 spinoff, evolving through acquisitions and divestitures to focus on healthcare and plumbing services.
Acquired full ownership of VITAS in the early 2000s, maintaining Roto-Rooter as a cash-generating business.
Maintains transparency for investors, allowing easy sum-of-the-parts analysis.
Both businesses are market leaders with strong cash flow and have been held for over 20 years.
Financial performance and capital allocation
Adjusted net income for VITAS grew 10.8% annually, Roto-Rooter 14.4%, and overall 21.7% over 21 years.
Share count reduced from 27 million to 15 million, enhancing per-share metrics.
$2.5 billion returned to shareholders via dividends and buybacks.
No debt and $200 million in cash on the balance sheet.
Free cash flow is about $300 million, supporting ongoing investments and buybacks.
Roto-Rooter business update
Experienced pandemic-driven demand surge, followed by weaker performance in 2023–2024.
Long-term outlook remains optimistic, expecting a return to 4%-6% growth.
Cash flow from Roto-Rooter supports other business growth and share repurchases.
Latest events from Chemed
- 2025 revenue rose 4.1%, but earnings fell; 2026 guidance anticipates stronger H2 growth.CHE
Q4 20253 Mar 2026 - Sustained EPS growth, Medicare cap management, and digital innovation drive robust 2024 results.CHE
BofA Securities 2025 Healthcare Conference2 Mar 2026 - Q2 2024 featured robust VITAS growth, Roto-Rooter declines, and raised full-year guidance.CHE
Q2 20242 Feb 2026 - Expecting high single-digit revenue and 10% EPS growth, with robust M&A and expansion plans.CHE
Jefferies 2024 Global Healthcare Conference31 Jan 2026 - VITAS growth offset Roto-Rooter softness, driving higher revenue and raised 2024 EPS guidance.CHE
Q3 202417 Jan 2026 - VITAS posts strong growth while Roto-Rooter pivots strategy amid rising competition.CHE
UBS Global Healthcare Conference 202414 Jan 2026 - Strong hospice growth and stable margins expected, with disciplined M&A and Roto-Rooter recovery underway.CHE
Bank of America Home Care Conference11 Jan 2026 - Hospice and Roto-Rooter show steady growth, with capital focused on acquisitions and buybacks.CHE
Oppenheimer 35th Annual Health Care MedTech and Services Conference26 Dec 2025 - VITAS drove record growth, offsetting Roto-Rooter softness; 2025 outlook remains positive.CHE
Q4 202423 Dec 2025